BioWorld

June 13, 2003

View Archived Issues

Mouse Leukemic Virus, HIV Rank First, Second In Gene Therapy Sweepstakes - But Oops Factor!

Read More

Onyx Cuts Staff Further, Shifts Entire Focus To Bayer Program

Read More

InterMune Falls On Lowered Guidance; Reports Positive Data

Read More

Durect Seeking $50M Through Offering Of Convertible Notes

Read More

Northfield Gets Positive News On Blood Product; Hemosol Set Back

Read More

Other News To Note

Read More

Pozen Licenses Migraine Drug To GSK In Potential $160M Deal

Pozen Inc. could garner up to at least $160 million after entering a deal with GlaxoSmithKline plc surrounding a migraine treatment. (BioWorld Today) Read More

Maxim Gets Back On Track After Reporting Positive Ceplene Data

Read More